Scarica l'app Stockscreener
1.39
0.72%
0.00
Dopo l'orario di chiusura:
1.38
-0.01
-0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$1.39
Aprire:
$1.39
Volume 24 ore:
950.23K
Relative Volume:
1.05
Capitalizzazione di mercato:
$148.18M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-4.0882
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
+0.00%
1M Prestazione:
-37.78%
6M Prestazione:
-60.45%
1 anno Prestazione:
-67.67%
Intervallo 1D:
$1.38
$1.41
Intervallo di 1 settimana:
$1.37
$1.48
Portata 52W:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.39 | 149.25M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
131.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.39 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.41 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.17 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.26 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
Quant Models Detect Momentum Reversal in MaxCyte Inc.Quarterly Trade Review & High Conviction Trade Alerts - newsyoung.net
MaxCyte Inc. Rebound Backed by Sentiment ShiftPrice Action & Fast Moving Stock Trade Plans - beatles.ru
What makes MaxCyte Inc. stock price move sharplyJuly 2025 Chart Watch & Weekly High Return Forecasts - classian.co.kr
MaxCyte Inc. Testing Reversal Zone on Weekly ChartWeekly Trade Review & Fast Gain Swing Trade Alerts - metal.it
MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks
What machine learning models say about MaxCyte Inc.IPO Watch & Reliable Breakout Forecasts - Newser
Why MaxCyte Inc. is moving todayJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
What MACD and RSI say about MaxCyte Inc.2025 Biggest Moves & Fast Moving Market Watchlists - Newser
Analyzing the Impact of Earnings Reports on MaxCyte Inc Inc. (MXCT) Price Performance - investchronicle.com
Signal strength of MaxCyte Inc. stock in tech scannersWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Maxcyte Stock Soars 10.87% on Insider Buying - AInvest
Volume spikes in MaxCyte Inc. stock – what they meanIPO Watch & Weekly Top Stock Performers List - Newser
Custom strategy builders for tracking MaxCyte Inc.Treasury Yields & Safe Swing Trade Setup Alerts - Newser
Douglas buys $111k in Maxcyte shares By Investing.com - Investing.com South Africa
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 - Investing.com
Masoud Maher buys Maxcyte (MXCT) shares worth $102,915 By Investing.com - Investing.com Nigeria
Brooke William buys Maxcyte (MXCT) shares worth $64,500 By Investing.com - Investing.com Canada
Maxcyte CFO Swirsky buys $64.5k in shares By Investing.com - Investing.com Canada
Erck Stanley C, Maxcyte director, buys $137k in MXCT stock - Investing.com Canada
Maxcyte CFO Swirsky buys $64.5k in shares - Investing.com
Brooke William buys Maxcyte (MXCT) shares worth $64,500 - Investing.com India
Maxcyte Director and CFO Make Significant Stock Purchases. - AInvest
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
Will MaxCyte Inc. continue its uptrendJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
MaxCyte (NASDAQ:MXCT) Earns Neutral Rating from BTIG Research - Defense World
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chart based exit strategy for MaxCyte Inc.Oversold Stock Bounce Playbook Generator - Newser
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com South Africa
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
BTIG Downgrades Maxcyte Neutral from Buy Rating - AInvest
MaxCyte signs platform license agreement with Adicet Bio - MSN
Is MaxCyte Inc. Forming a Consolidation BaseMarket Surge Signal for Swing Traders Triggered - beatles.ru
MaxCyte (NASDAQ:MXCT) Lowered to Sell Rating by Wall Street Zen - Defense World
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.82%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):